BIND Therapeutics (BIND) Surges on Upgrade

BIND Therapeutics, Inc. (BIND) shares are trading higher by nearly 13% to $6.40 in early trading after the company was initiated this morning with an ‘Outperform’ rating and $14.00 price target by analysts at Oppenheimer. The firm’s 12-month base case estimate suggests a potential upside of 120% from the stock’s current pps. Fundamentally, BIND shows […] View the full post at: BIND Therapeutics (BIND) Surges on Upgrade Related posts: Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock American Southern Bank Goes Bust Rents in London Crashing to 1991 Levels
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.